Sharemaestro company-news research for Bausch + Lomb Corporation (BLCO), showing current tone, evidence confidence, direct company coverage, sector and industry context, completed price response and the source headlines used on the page. Scores describe published news evidence. Confidence describes the amount, freshness, source breadth and direct company relevance of that evidence. Price context is shown separately.
TOR
Canada
Provisional evidence
Company news sentiment
Latest BLCO news and sentiment
Bausch + Lomb Corporation
Company headlines from the last 30 days, weighted by freshness, relevance, publisher quality and the strength of the wording. Price is shown separately.
30-day score51Neutral is 50
Early balanced news score
20/100 evidence confidence
100% direct company focus
16 current stories across 4 publishers
Current company news
Early balanced news score
16 company-specific stories are available, but there are not yet enough fresh stories from separate publishers for a firm reading.
Observed headline tone65/100
→
Published 30-day score51/100
Latest source headline
Bausch + Lomb (BLCO) Gains Clinical Backing As Investors Ask If The Valuation Case Holds
simplywall.st · 05 Sep 2026 14:35
Older, less relevant and less reliable stories count for less. Confidence is shown separately.
What supports the score
16 current stories are mapped specifically to BLCO.
The score uses 4 publishers rather than depending on one outlet.
What limits the score
The stories agree, but freshness-weighted evidence is only 0.083.
Confidence is 20/100, below the threshold for a firm score.
51/100
News scoreEarly balanced news score
20/100
Confidencethin evidence
100%/100
Company news16 company stories
94/100
Story agreement6/100 difference
News history
Daily score and story count over 30 days
11 Aug26 Aug09 Sep
News scoreStory count50 baseline
Confidence
How reliable the score is
Confidence uses the amount of news, separate publishers, direct company relevance, freshness and agreement. A high or low score is not automatically reliable.
Amount of evidence2
0.083 after freshness weightingSource breadth80
4 independent publishersCompany relevance100
share tied directly to this companyFreshness21
recency-weighted evidenceAgreement94
how closely stories agreePublisher mix49
less reliance on one publisherPrice and news history
Weekly price and news-score history
Company-specific news is present, but the evidence has not yet earned enough independent, fresh information weight for price confirmation to be treated as a firm signal.
26 completed price weeks23 comparable news-score weeks
One scoring method across the chart.Stored company headlines are recalculated at each weekly point with the current 30-day freshness weighting. Old published snapshots are left unchanged.
13 Mar09 Jun04 Sep
Weekly close, indexedSentiment score
WeekNews scoreCloseWeekly move
04 Sep 202652CAD 24.98+4.9%
28 Aug 202651CAD 23.82-0.4%
21 Aug 202653CAD 23.92+1.4%
14 Aug 202656CAD 23.59+1.4%
07 Aug 202658CAD 23.27-1.6%
31 Jul 202663CAD 23.66+4.1%
24 Jul 202650CAD 22.719999+0.1%
17 Jul 202650CAD 22.690001-0.9%
Provisional evidence
News subjects
What is shaping the score
Market update549 stories · 56%
Earnings584 stories · 25%
Guidance751 stories · 6%
Analyst action541 stories · 6%
Balance sheet501 stories · 6%
Source mix
Where the evidence comes from
simplywall.st653 stories · 19%
Wealth Awesome513 stories · 19%
Business Wire502 stories · 12%
DirectorsTalk Interviews661 stories · 6%
Kalkine Media571 stories · 6%
MT Newswires541 stories · 6%
AD HOC NEWS501 stories · 6%
Recurring subjects
Subjects appearing most often
Eye Health2Clinical Trials2Pharma1Ophthalmology1Medical Equipment1Medical Devices1Intrinsic Value1Future Cash Flows1Free Cash Flow1Fda Approval1
Earlier readings
How the score has changed
Past and present use the same method.Each point recalculates the previous 30 days of stored company headlines with today's scoring rules. The original stored snapshots remain unchanged.
27 Mar50 neutral07 Sep 04:10
ConstructiveBalanced or withheldCautious
Changes in the stored score
Scores are rebuilt from stored headlines with the current 30-day method. Days with no change are collapsed.
| Observed | Score | Move | Confidence | Stories | Status |
|---|---|---|---|---|---|
| 07 Sep 04:10 | 52 | +0 | 22/100 (-3) | 17 (-1) | Provisional |
| 05 Sep 23:59 | 52 | +0 | 25/100 (+1) | 18 (0) | Provisional |
| 03 Sep 23:59 | 52 | +0 | 24/100 (-1) | 18 (+1) | Provisional |
| 02 Sep 23:59 | 52 | +0 | 25/100 (-2) | 17 (0) | Provisional |
| 01 Sep 23:59 | 52 | -1 | 27/100 (-2) | 17 (+1) | Provisional |
| 31 Aug 23:59 | 53 | +2 | 29/100 (+11) | 16 (0) | Provisional |
| 29 Aug 23:59 | 51 | -1 | 18/100 (-1) | 16 (-10) | Provisional |
| 25 Aug 23:59 | 52 | +0 | 19/100 (-1) | 26 (+3) | Provisional |
Source headlines
The news behind the score
Only company-specific stories enter this score. The latest 30 days are shown newest first, with newer stories weighted more heavily and duplicate coverage combined.
#157Tone
simplywall.stDirect company coverageScored from headline
Bausch + Lomb (BLCO) Gains Clinical Backing As Investors Ask If The Valuation Case Holds
- Published
- 05 Sep 2026 14:35
- News subject
- Market update
- Why this score
- Positive financial language
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Story strength
- Medium · 37/100
- 30-day weight
- 23% of the score · 3.9d old
- Duplicates
- 1 consolidated
#2—Not directional
AD HOC NEWSDirect company coverageScored from headline
Bausch + Lomb stock rises on survey-driven dry eye focus
- Published
- 03 Sep 2026 11:02
- News subject
- Market update
- Why this score
- The headline reports news without a clear direction
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 6.1d old
- Duplicates
- 1 consolidated
#3—Not directional
Business WireDirect company coverageStored article
Bausch + Lomb Announces New Published Research on enVista Aspire™ Real World Experience
Multicenter retrospective case series published in Ophthalmology and Therapy Results demonstrate enVista Aspire and enVista Aspire toric deliver good distance and functional intermediate vision in a majority of patients Study shows these enhanced monofocal lenses can meet digital demands modern cataract patients face This paper and other data on enVista Aspire can be found on Bausch + Lomb's new Eye Care Professional Hub VAUGHAN, Ontario, September 02, 2026--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better t
Cataract SurgeryEye HealthMedical DevicesOphthalmology
- Published
- 02 Sep 2026 11:00
- News subject
- Earnings
- Why this score
- The headline reports news without a clear direction
- Company focus
- Shared story · 78%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 7.1d old
- Duplicates
- 1 consolidated
#4—Not directional
Business WireDirect company coverageScored from headline
Most Women Don't Recognize Dry Eye as a Symptom of Perimenopause and Menopause, New Bausch + Lomb Survey Finds
- Published
- 01 Sep 2026 10:58
- News subject
- Market update
- Why this score
- The headline reports news without a clear direction
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 8.1d old
- Duplicates
- 1 consolidated
#566Tone
DirectorsTalk InterviewsDirect company coverageScored from headline
Bausch + Lomb Corporation (BLCO) Stock Report: Analyzing a 9.10% Revenue Growth in the Healthcare Sector
- Published
- 31 Aug 2026 09:21
- News subject
- Earnings
- Why this score
- Operating growth
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Story strength
- Medium · 49/100
- 30-day weight
- 57.3% of the score · 9.1d old
- Duplicates
- 1 consolidated
#6—Not directional
Simply Wall St.Direct company coverageStored article
Bausch + Lomb (BLCO) Stock Trades Below Fair Value As Caution Lingers
Bausch + Lomb stock has delivered a 17.2% return over the past year, yet several valuation checks still flag the shares as cheap relative to an intrinsic value estimate and to market multiples. For investors, the puzzle is why a stock with a high value score and an intrinsic estimate that screens as undervalued is not pricing in more of that potential. The 17.2% 1 year return suggests Bausch + Lomb has already rewarded patient holders, but the move has not erased what some models see as a discount. Progress in late stage eye therapy trials can support expectations for future cash flows, while
Clinical TrialsDiscounted Cash FlowFree Cash FlowFuture Cash FlowsIntrinsic ValueMedical Equipment
- Published
- 29 Aug 2026 23:06
- News subject
- Balance sheet
- Why this score
- Positive valuation view
- Company focus
- Shared story · 78%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 10.6d old
- Duplicates
- 1 consolidated
#7—Not directional
ZacksDirect company coverageStored article
Bausch + Lomb Advances Two First-in-Class Eye Health Therapies
Bausch + Lomb BLCO recently announced that two first-in-class pharmaceutical pipeline candidates will advance to the next stages of clinical development following positive trial results. The programs include a dual-action eye drop for dry eye disease that is moving into Phase 3 and BL1332, an investigational treatment for ocular surface pain, which will continue in Phase 2. Per Bausch + Lomb CEO Brent Saunders, helping people see better and live better starts with tackling challenges patients face every day. The trial results support the company's approach to developing differentiated treatmen
Clinical TrialsEarningsEarnings GrowthEarnings Per ShareEye HealthFda Approval
- Published
- 25 Aug 2026 15:53
- News subject
- Earnings
- Why this score
- Positive financial language
- Company focus
- Shared story · 78%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 14.9d old
- Duplicates
- 2 consolidated
#8—Not directional
StockStoryDirect company coverageScored from headline
A Look Back at Medical Devices & Supplies - Specialty Stocks’ Q2 Earnings: Bausch + Lomb (NYSE:BLCO) Vs The Rest Of The Pack
- Published
- 25 Aug 2026 10:27
- News subject
- Earnings
- Why this score
- The headline reports news without a clear direction
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 15.1d old
- Duplicates
- 1 consolidated
#9—Not directional
Wealth AwesomeDirect company coverageScored from headline
What's Going On With Bausch + Lomb Corp Stock Tuesday?
- Published
- 25 Aug 2026 05:01
- News subject
- Market update
- Why this score
- The headline reports news without a clear direction
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 15.3d old
- Duplicates
- 1 consolidated
#10—Not directional
MarketBeatDirect company coverageScored from headline
Bausch + Lomb Advances Dry Eye Drug to Phase III as Pain Candidate Hits Phase Ib Goal
- Published
- 25 Aug 2026 01:01
- News subject
- Market update
- Why this score
- The headline reports news without a clear direction
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 15.5d old
- Duplicates
- 1 consolidated
#11—Not directional
MT NewswiresDirect company coverageStored article
Bausch + Lomb Plans to Advance Dual-Action Eye Drop Targeting Evaporative and Inflammatory Dry Eye Disease to Phase 3
Bausch + Lomb (BLCO) said late Monday it plans to advance two of its pharmaceutical pipeline assets PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade Already have a subscription? Sign in
Pharma
- Published
- 24 Aug 2026 21:38
- News subject
- Analyst action
- Why this score
- Positive financial language
- Company focus
- Shared story · 78%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 15.6d old
- Duplicates
- 1 consolidated
#1243Tone
simplywall.stDirect company coverageScored from headline
Did Bausch + Lomb’s (BLCO) Board Overhaul Amid Weak Returns Just Shift Its Investment Narrative?
- Published
- 20 Aug 2026 07:00
- News subject
- Market update
- Why this score
- Negative financial language
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Story strength
- Low · 28/100
- 30-day weight
- <0.1% of the score · 20.2d old
- Duplicates
- 1 consolidated
#1357Tone
Wealth AwesomeDirect company coverageScored from headline
Why Bausch + Lomb Corp stock is rising today
- Published
- 18 Aug 2026 15:46
- News subject
- Market update
- Why this score
- Positive financial language
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Story strength
- Low · 28/100
- 30-day weight
- <0.1% of the score · 21.9d old
- Duplicates
- 1 consolidated
#14—Not directional
Wealth AwesomeDirect company coverageScored from headline
What's Going On With Bausch + Lomb Corp Stock Tuesday?
- Published
- 18 Aug 2026 05:30
- News subject
- Market update
- Why this score
- The headline reports news without a clear direction
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 22.3d old
- Duplicates
- 1 consolidated
#1557Tone
Kalkine MediaDirect company coverageScored from headline
Why Could Bausch + Lomb (TSX:BLCO) Gain From Aging Demographics?
- Published
- 14 Aug 2026 17:07
- News subject
- Market update
- Why this score
- Positive financial language
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Story strength
- Low · 28/100
- 30-day weight
- <0.1% of the score · 25.8d old
- Duplicates
- 1 consolidated
#1675Tone
simplywall.stDirect company coverageScored from headline
Is Bausch + Lomb’s Raised 2026 Outlook And Board Refresh Altering The Investment Case For BLCO?
- Published
- 12 Aug 2026 18:32
- News subject
- Guidance
- Why this score
- Guidance raised
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Story strength
- Medium · 54/100
- 30-day weight
- 19.5% of the score · 27.7d old
- Duplicates
- 1 consolidated
Earlier company news
BLCO news archive
Stored newest first for historical research. It starts after the newest three pages above and then continues through older news. Each archive page is loaded only when it is opened.
Older news is kept in the archive
There are 52 older BLCO headlines. Open one page at a time when you need them.
Open older archiveProvider matches checked
Provider mentions not used in the score
A news provider linked these stories to BLCO, but the headline and available text are not mainly about Bausch + Lomb Corporation. They are kept here for transparency and do not affect the score, confidence, history or wider market totals.
Aug112026
seekingalpha.comProvider mentionNot included in score
These stocks have some of Wall Street’s lowest short interest
[short sale] abluecup Stocks including Apple, Alphabet, Exxon Mobil, and JPMorgan are among the companies with relatively low short interest, according to a screen of stocks with market capitalizations above $2B. The screen includes stocks with short interest between 1% and 2% of shares outstanding, highlighting companies with relatively limited bearish positioning. Apple (AAPL [https://seekingalpha.com/symbol/AAPL]) has the lowest short interest in the screen at 1.00%, followed by Alphabet (GOOG [https://seekingalpha.com/symbol/GOOG]) and InnIO (INIO [https://seekingalpha.com/symbol/INIO]) at
- Published
- 11 Aug 2026 14:40
- Provider record
- eodhd
- Use in sentiment
- Not scored
- Reason
- Company is not the main subject
How the page works
How to read the score
It describes the weighted balance of qualifying headlines. A score of 50 can mean balanced news or that there is not enough evidence; the status label explains which.
Confidence measures depth, source breadth, direct relevance, freshness and agreement. It does not rise merely because the tone is extreme.
Weekly price response, trend and fair-value position test whether the market is accepting or rejecting the news. They never rewrite the news score.
It measures news already published. It is not a forecast, recommendation or price target.